Sharing Our Perspectives

Unveiling the Potential of GBA: A Key Player in Parkinson’s Disease Precision

Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.

Deciphering Parkinson’s Complexity: Insights from Professor Tiago Fleming Outeiro

Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.

Advancing GBA Modulator GT-02287: A Promising Treatment for Parkinson’s Disease

Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.

More of Our Perspectives

Conversations with Dr. Manolo Bellotto

Conversations with Dr. Manolo Bellotto – Part II

Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story.  You can follow him on : Twitter : @ManoloBellotto LinkedIn :

Protein Degradation via PROTAC

Protein Degradation via PROTAC

What is PROTAC? PROTAC, which is an acronym for proteolysis targeting chimera, is a class of heterobifunctional molecules that can be used to target specific proteins for degradation